cc-5013
Myeloid Disorders
Medical College of WisconsinPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Myeloid Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zanubrutinib Medical College of Wisconsin | Phase 2 | B |
Same molecule, other indications
cc-5013 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →